Quantamental Technologies LLC acquired a new stake in Novo Nordisk A/S (NYSE:NVO) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 776 shares of the company’s stock, valued at approximately $41,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Camarda Financial Advisors LLC purchased a new position in shares of Novo Nordisk A/S in the 1st quarter valued at approximately $28,000. Bruderman Asset Management LLC purchased a new position in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $29,000. WP Advisors LLC purchased a new position in shares of Novo Nordisk A/S in the 1st quarter valued at approximately $39,000. Pinnacle Bank purchased a new position in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $40,000. Finally, Enterprise Financial Services Corp grew its stake in shares of Novo Nordisk A/S by 46.4% in the 1st quarter. Enterprise Financial Services Corp now owns 817 shares of the company’s stock valued at $42,000 after purchasing an additional 259 shares during the last quarter. Institutional investors and hedge funds own 7.04% of the company’s stock.

NVO opened at $46.94 on Thursday. The company has a quick ratio of 0.66, a current ratio of 0.96 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $115.75 billion, a PE ratio of 18.63, a price-to-earnings-growth ratio of 2.12 and a beta of 0.56. Novo Nordisk A/S has a 12 month low of $41.23 and a 12 month high of $52.83.

Several research analysts have weighed in on the company. Pareto Securities downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, April 30th. Credit Suisse Group upgraded Novo Nordisk A/S from a “neutral” rating to an “outperform” rating in a research note on Monday, April 29th. Zacks Investment Research downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Wednesday, February 13th. Handelsbanken downgraded Novo Nordisk A/S from a “buy” rating to an “accumulate” rating and set a $48.61 target price on the stock. in a research note on Monday, February 4th. Finally, BNP Paribas assumed coverage on Novo Nordisk A/S in a research note on Tuesday, January 29th. They issued an “outperform” rating on the stock. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and seven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $52.31.

WARNING: This article was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.dailypolitical.com/2019/05/16/quantamental-technologies-llc-invests-41000-in-novo-nordisk-a-s-nvo.html.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Featured Article: Risk Tolerance

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.